Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,553Revenue $M2.6Net Margin (%)0Z-Score72.9
Enterprise Value $M1,426EPS $-0.6Operating Margin %0F-Score3
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)0Higher ROA y-yY
Price/Book13.110-y EBITDA Growth Rate %-37.3Quick Ratio11.7Cash flow > EarningsY
Price/Sales05-y EBITDA Growth Rate %-6.5Current Ratio11.7Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-40.4Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-43.3Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M100ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with ACHN

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ACHNJean-Marie Eveillard 2014-03-31 Sold Out -0.01%$3.08 - $4.2
($3.5)
$ 15.49343%Sold Out0
ACHNJean-Marie Eveillard 2013-12-31 Buy 0.01%$2.43 - $3.46
($2.9)
$ 15.49434%New holding, 600000 sh.600,000
ACHNJohn Burbank 2012-12-31 Sold Out -0.24%$7.2 - $11.1
($8.86)
$ 15.4975%Sold Out0
ACHNJohn Burbank 2012-09-30 Buy 0.24%$5.61 - $10.41
($7.06)
$ 15.49119%New holding, 500000 sh.500,000
ACHNGeorge Soros 2012-06-30 Sold Out -0.04%$5.94 - $10.95
($7.34)
$ 15.49111%Sold Out0
ACHNGeorge Soros 2012-03-31 Reduce-0.09%$7.71 - $12.375
($9.57)
$ 15.4962%Reduce -50%250,000
ACHNGeorge Soros 2011-12-31 Add0.16%$4.01 - $8
($6.15)
$ 15.49152%Add 2132.14%500,000
ACHNGeorge Soros 2011-09-30 Buy $4.63 - $8.31
($6.37)
$ 15.49143%New holding, 22400 sh.22,400
ACHNDavid Swensen 2007-12-31 Sold Out -0.06%$4.29 - $5.46
($4.9)
$ 15.49216%Sold Out0
ACHNDavid Swensen 2007-06-30 Buy 0.07%$5.02 - $6.16
($5.6)
$ 15.49177%New holding, 39955 sh.39,955
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ACHN is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


ACHN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
RA CAPITAL MANAGEMENT, LLC 2014-09-30Sell1,332,014$10.251.86view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-09-26Sell2,372,915$11.1738.68view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-09-23Sell2,595,071$11.2937.2view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-09-11Sell1,704,362$12.4524.42view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-09-11Sell1,704,362$20356.3-99.92view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-09-02Sell835,293$11.6333.19view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-08-27Sell2,711,352$11.3336.72view
Truitt JosephEVP, Chief Commercial Officer 2014-08-25Sell25,000$10.8243.16view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-08-18Sell4,235,000$9.5362.54view
Deshpande MilindPresident and CEO 2014-08-18Sell216,624$1054.9view

Press Releases about ACHN :

    Quarterly/Annual Reports about ACHN:

    News about ACHN:

    Articles On GuruFocus.com
    Weekly CEO Sells Highlight: Achillion Pharmaceutical Inc, Protective Life Corp, Host Hotels & Resort Aug 25 2014 
    Top 4 Insider Buys of Last Week Jun 10 2013 
    comment on ACHN Mar 15 2013 
    comment on ACHN Mar 09 2013 
    Achillion Will Surge If New Drug Is Successful Apr 21 2012 
    Weekly CEO Sells Highlight: Achillion Pharmaceuticals Inc, Monster Beverage Corp, CarMax Inc, and Im Jan 23 2012 
    Weekly CEO Sells Highlight: UNH, LRY, ACHN, RPM Jan 16 2012 
    Achillion Pharmaceuticals Inc. Reports Operating Results (10-Q) Oct 27 2010 
    Achillion Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 13 2010 
    Achillion Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 03 2009 

    More From Other Websites
    Achillion Pharma Takeout Less Likely Following Subpar Hep C Drug Results Dec 22 2014
    Achillion rises on new hepatitis C drug study Dec 22 2014
    Achillion rises on new hepatitis C drug study Dec 22 2014
    Achillion Says Hepatitis Studies Show Strong Results Dec 22 2014
    Achillion Pharmaceuticals Shares Volatile Following Hepatitis C Treatment News Dec 22 2014
    Stock Futures Point Higher; AbbVie Surges, Gilead Dives Dec 22 2014
    ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 22 2014
    Achillion Shows Potential for "Best-in-Disease" HCV Regimen - 100% SVR4 Following a Dual 6-Week... Dec 22 2014
    6:33 am Achillion Pharma announced positive interim results from two studies supporting a short... Dec 22 2014
    Achillion Shows Potential for "Best-in-Disease" HCV Regimen - 100% SVR4 Following a Dual 6-Week... Dec 22 2014
    Six Biotech and Technology Stocks With Strong Technical Set-Ups Dec 18 2014
    These 4 Biotech Stocks Have Been On Fire Dec 08 2014
    5 Stock-Moving Medtech Events This December Nov 28 2014
    Achillion to Present at Two Upcoming Investor Conferences Nov 25 2014
    Achillion to Present at Two Upcoming Investor Conferences Nov 25 2014
    Deutsche Bank Mystified By 18% Jump In Achillion Pharmaceuticals Nov 13 2014
    Will Achillion Pharmaceuticals (ACHN) Continue to Surge Higher? Nov 13 2014
    Achillion Pharmaceuticals (ACHN) Stock Rises on Positive Hepatitis C Drug Results Nov 12 2014
    Achillion Jumps on Encouraging Data on its HCV Candidate Nov 11 2014
    ACHILLION PHARMACEUTICALS INC Financials Nov 11 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK